ESMO 2017 | What is durvalumab’s future as a treatment option in lung cancer?

Luis Paz-Ares, MD, from The University Hospital 12 de Octubre, Madrid, Spain talks to us about the PACIFIC trial (NCT02125461), a Phase III study assessing the efficacy of durvalumab in the treatment of unresectable non-small cell lung cancer following chemoradiation. Prof. Paz-Ares talks us through the results of the trial and explains what these tell us about the future of durvalumab as a treatment option. He also discusses when follow-up assessments of the drug will be made. This interview was recorded at the 2017 European Society for Medical Oncology (ESMO) conference held in Madrid, Spain.